Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, chief executive officer of Serum Institute
of India (SII), expects the restrictions on export of Covid vaccines to ease within two months, provided that India has created enough stockpile to weather a third wave.
Raw material supplies for the Novavax vaccine
have improved compared to March, and SII plans to announce its monthly production plan in December, Poonawalla told the media on Friday.
“There was no ban on exports, but there were temporary restrictions, and rightly so. I think these will slowly ease in the next month or two, but I don’t want to venture a guess. But it will happen very soon,” he said, adding that India is very close to a point where there is more than enough vaccine
Poonawalla said easing the export restrictions is a government of India’s decision, and he will go by what the Centre feels is appropriate.
“The Centre has to balance the needs of the country and stockpile vaccines for India in case of the third and fourth waves. Taking lessons from the first and second waves, the government is rightly being very cautious,” he said.
Stepping up Covid fight
Paediatric Covovax may be ready for approval by Jan-Feb
Raw material supplies for Novavax vaccine have improved
SII to announce monthly Covovax production in December
To produce 200 mn monthly doses of Covishield from October
SII is expanding its Covishield capacity, which now stands at around 160 million doses a month. From October, it is expected to touch 200 million doses a month.
On the other hand, the production of the Novavax vaccine is not constrained by SII’s capacities, but by raw materials, Poonawalla said. SII is working on developing alternative vendor sources for critical raw materials. “Developing new supplies takes time. The silver lining is we have got people who can make quality raw materials, but they are inundated with orders from different vaccine companies
– from Korea, China, Europe, etc,” he added.
SII is trying its best to scale up the production of the Novavax vaccine, Poonawalla said, and that there have been major improvements in raw material supplies since March. “We will wait and see, and in December, for sure, we can comment on what our monthly production will be,” he said.
As for the Novavax vaccine’s clinical trials on paediatric population, Poonawalla said the company has started trials, and three to four months is the minimum timeframe for that. By January-February, there is a possibility that Covovax (SII-manufactured Novavax vaccine) could be ready for approval for use in kids.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.